CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled / 16 target
Drug / intervention
Wide-spectrum nutritional supplement +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03835117
NCT03835117Phase 2CompletedUpdate Overdue (0.2/mo)Completion was 47mo ago

Effect of a Wide Spectrum Nutritional Supplement on Mitochondrial Function in Children With Autism Spectrum Disorder (ASD)

Rossignol Medical Center·interventional·Posted Feb 8, 2019·Updated Jun 30, 2026

In Brief

A Phase 2 clinical trial evaluating Wide-spectrum nutritional supplement and Placebo for Autism Spectrum Disorder. Completed, enrolled 16 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

The objective of this study is to evaluate the metabolic effects of a comprehensive wide-spectrum supplement for children with ASD to determine whether it physiologically targets mitochondrial pathways known to be abnormal in children with ASD.The intervention is a commonly used wide-spectrum nutritional supplement, which is theoretically designed to normalize mitochondrial function. The investigators aim to determine if the supplement does have the hypothesized effect on physiology in individuals with ASD. The investigator will enroll up to 50 children, aged 4 to 14 years of age with confirmed ASD and mitochondrial dysfunction, and participation will last 26 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedFeb 8, 2019
Enrollment StartFeb 1, 2020
Primary CompletionJul 31, 2022
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 7.4 years ago

Arms & Interventions

Wide-spectrum nutritional supplementexperimental

The Wide-spectrum nutritional supplement used will be a combination of NeuroNeeds: SpectrumNeeds and QNeeds. Weight based dosing will be used. The daily serving size will be divided into two oral daily doses in the form of a powder which can be mixed into liquid or food. Together, there are 34 different dietary supplements in the products. Except for ubiquinol, all of these nutrients are provided in a powder form in SpectrumNeeds. Ubiquinol is provided separately in QNeeds gel capsules. These capsules can be swallowed whole, or cut with scissors and the contents squeezed out and added to SpectrumNeeds just before ingestion.

Drug: Wide-spectrum nutritional supplement
Placebo controlplacebo_comparator

Participants randomized to receive placebo will take placebo in an oral form divided into powder and a gel capsule in the same manner as treatment. For the second phase of the cross over, participants will be part of the opposite group they were assigned to in Phase I (Placebo or Treatment). Quantities for placebo or treatment will match across phases for each subject, utilizing the same weight based dosing.

Other: Placebo

Interventions

Wide-spectrum nutritional supplementdrug

Comprehensive powder with 33 dietary supplements and 1 dietary supplement via gel capsule.

Placeboother

Inactive placebo comparator